Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2010 3
2011 2
2012 2
2013 1
2014 3
2015 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Targeting translation initiation in breast cancer.
Akcakanat A, Hong DS, Meric-Bernstam F. Akcakanat A, et al. Translation (Austin). 2014 Apr 29;2(1):e28968. doi: 10.4161/trla.28968. eCollection 2014. Translation (Austin). 2014. PMID: 26779407 Free PMC article. Review.
Targeting the PI3-kinase/Akt/mTOR signaling pathway.
Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Hassan B, et al. Surg Oncol Clin N Am. 2013 Oct;22(4):641-64. doi: 10.1016/j.soc.2013.06.008. Epub 2013 Aug 6. Surg Oncol Clin N Am. 2013. PMID: 24012393 Free PMC article. Review.
Metformin: a therapeutic opportunity in breast cancer.
Gonzalez-Angulo AM, Meric-Bernstam F. Gonzalez-Angulo AM, et al. Clin Cancer Res. 2010 Mar 15;16(6):1695-700. doi: 10.1158/1078-0432.CCR-09-1805. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215559 Free PMC article. Review.
Rapamycin regulates the phosphorylation of rictor.
Akcakanat A, Singh G, Hung MC, Meric-Bernstam F. Akcakanat A, et al. Biochem Biophys Res Commun. 2007 Oct 19;362(2):330-3. doi: 10.1016/j.bbrc.2007.07.151. Epub 2007 Aug 8. Biochem Biophys Res Commun. 2007. PMID: 17707343 Free PMC article.
Influence of biospecimen variables on proteomic biomarkers in breast cancer.
Meric-Bernstam F, Akcakanat A, Chen H, Sahin A, Tarco E, Carkaci S, Adrada BE, Singh G, Do KA, Garces ZM, Mittendorf E, Babiera G, Bedrosian I, Hwang R, Krishnamurthy S, Symmans WF, Gonzalez-Angulo AM, Mills GB. Meric-Bernstam F, et al. Clin Cancer Res. 2014 Jul 15;20(14):3870-83. doi: 10.1158/1078-0432.CCR-13-1507. Epub 2014 Jun 3. Clin Cancer Res. 2014. PMID: 24895461 Free PMC article.
Targeting PI3K/mTOR signaling in cancer.
Emerling BM, Akcakanat A. Emerling BM, et al. Cancer Res. 2011 Dec 15;71(24):7351-9. doi: 10.1158/0008-5472.CAN-11-1699. Epub 2011 Oct 10. Cancer Res. 2011. PMID: 21987725
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Xing Y, et al. Breast Cancer Res. 2019 Jul 5;21(1):78. doi: 10.1186/s13058-019-1154-8. Breast Cancer Res. 2019. PMID: 31277699 Free PMC article. Clinical Trial.
15 results